ArticleInflammopharmacology2025
Mechanistic investigation of methadone, tolfenamic acid, and cilnidipine in traumatic brain injury: a novel multi-target perspective outcome of network pharmacology.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethadone (MTD) is a synthetic opioid, N-Methyl-D-Aspartate (NMDA) antagonist, Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug (NSAID), and Cilnidipine (CLD) is a calcium channel blocker widely used for the management of various neurological disorders and their associated complications. Investigating the mechanism of MTD, TA, and CLD drugs with Traumatic Brain Injury (TBI) protein has become easier with the advent of network pharmacology.
aimThe purpose of this study is to use network pharmacology, a contemporary method, to examine the mechanisms of MTD, TA, and CLD in TBI. MATERIALS AND
methodsA protein-protein interaction (PPI) network was used to determine the primary therapeutic targets of MTD, TA, and CLD against TBI. Several extensive databases (Pubchem, Swiss target prediction database, String and DisGeNET database, ADMET lab2.0, and Swiss ADME database) were consulted to collect MTD, TA, and CLD linked targets and genes relevant to TBI. Drug-Drug interactions (DDIs) of MTD, TA, and CLD were also checked using Drug Bank, Lexicomp
resultsMTD, TA, and CLD were found to have important pathways according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. MTD inhibits the NOS1, NOS2, NOS3, and MPO, CXCR4 activated gene pathways and stimulates the DRD2, SLC6A3, SLC6A4, SLC18A2, HTR1A, and AKT1 deactivated gene pathways. TA inhibits the GRIN1, MAPK1, and COX-II activated gene pathways. CLD inhibits the MAP2K1, CACNA1C, CACNA1D, PDE4D, CASP3, mTOR, PTGS2, SCN9N, and GSK3B, and stimulates the IGF1R, DRD2, SHH, HTR2A, FASN, CNR1, ABCB1, and PIK3CA deactivated gene pathways. The pharmacokinetic and toxicity profile was checked using ADMET analysis to make sure that it aligned to the optimum values. Drug-drug interactions (DDIs) were assessed to evaluate safety profile, and no interaction were found between MTD, TA and CLD.
conclusionsThis study identified a primary target for MTD such as NOS1, NOS2, NOS3, DRD2, DAT (SLC6A3), MPO, SLC6A4, CXCR4-C-X-C, AKT1, SLC/8A2, HTR1A; for TA: MAPK1, GRIN1 and for CLD: IGF1R, DRD2, SHH, MAP2K1, CACNA1D, HTR2A, PDE4D, CASP3, MTOR, FASN, PTGS2, SCN9N, CNR1, CACNA1C, ABCB1, PIK3CA, GSK3B in the mechanistic regulation of TBI by reducing the activation of several pathways linked to development of TBI.
Indexed as
Identifiers
40622465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.